Overview

Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes

Status:
Unknown status

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

In this study, the investigators will assess the efficacy and tolerability of a novel, initial triple combination therapy with metformin, saxaglipitin, and dapagliflozin, compared to conventional stepwise add-on therapy in drug-naïve patients with recently onset type 2 diabetes.

Phase:

Phase 3

Details

Lead Sponsor:

Korea University Anam Hospital

Collaborator:

AstraZeneca

Treatments:

Dapagliflozin
Glimepiride
Metformin
Saxagliptin
Sitagliptin Phosphate